Media Releases - 2006

	Orchid signs deal with Biovitrum in drug discovery field
	Orchid’s Q2 FY07 net profit rises to Rs 29 crore Total revenue higher at Rs 246 crore
	Orchid receives USFDA approvals for Cefadroxil ANDAs
	Orchid’s Formulation and API facilities approved by the UK MHRA Will provide a significant boost to the European generic foray
	Orchid receives USFDA approvals for Cefotaxime Injection ANDAs Mature generic product with limited competition
	Orchid undertakes structural consolidation of global discovery research Acquires 100% of US Discovery entity, Bexel Pharmaceuticals
	Orchid’s Q1 FY 2006-07 net profit up by 99% Revenues driven by increased foray into the advanced markets
	Orchid recieves USFDA approval for Cephalexin oral suspension ANDA
	Orchid Orchid registers turnover of Rs 889 crore during FY 2005-06 Net profit zooms by 167% to Rs 83 crore US Generics entry propels all-round growth
	Orchid enters into long term R&D tie-up with Pfizer for new animal health products
	Orchid receives USFDA approval for Cefoxitin Injection ANDA
	Orchid registers turnover of Rs 238 crore during Q3 FY 2005-06
	Orchid receives USFDA approval for Cefprozil oral suspension ANDA